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ABSTRACT
The adoption of CRISPR systems for the generation
of synthetic transcription factors has greatly simpli-
fied the process for upregulating endogenous gene
expression, with a plethora of applications in cell bi-
ology, bioproduction and cell reprogramming. The
recently discovered CRISPR/Cas12a (Cas12a) sys-
tems offer extended potential, as Cas12a is capa-
ble of processing its own crRNA array, to provide
multiple individual crRNAs for subsequent targeting
from a single transcript. Here we show the applica-
tion of dFnCas12a-VPR in mammalian cells, with the
Francisella novicida Cas12a (FnCas12a) possessing
a shorter PAM sequence than Acidaminococcus sp.
(As) or Lachnospiraceae bacterium (Lb) variants, en-
abling denser targeting of genomic loci, while per-
forming just as well or even better than the other
variants. We observe that synergistic activation and
multiplexing can be achieved using crRNA arrays but
also show that crRNAs expressed towards the 5′ of
6-crRNA arrays show evidence of enhanced activ-
ity. This not only represents a more flexible tool for
transcriptional modulation but further expands our
understanding of the design capabilities and limita-
tions when considering longer crRNA arrays for mul-
tiplexed targeting.
INTRODUCTION
Synthetic transcription factors are modular proteins com-
posed of DNA binding domains and transactivation do-
mains, which enable up-regulation of targeted genes. Whilst
a number of strategies have been developed (1), the appli-
cation of clustered regularly interspersed palindromic re-
peats (CRISPR) systems has greatly reduced the costs and
complexity associated with generating synthetic transcrip-
tion factors for targeting different loci (2).
A hybridised CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA) enables targeting of the
CRISPR associated protein 9 (Cas9) to a specific locus (3).
The spacer sequence within the crRNA confers target speci-
ficity, with binding and cleavage only occurring if the spacer
sequence is complementary to the target sequence. There
must also be a protospacer adjacent motif (PAM) sequence,
which varies based on the Cas9 species of origin, adjacent
to the target sequence. If the PAM sequence is present, then
Cas9 can transiently melt the DNA to enable infiltration by
the spacer sequence (4). Subsequently, if the spacer is com-
plementary to the target sequence, then Cas9 will bind and
cleave the target DNA.
The generation of a DNase inactive Cas9 variant (dCas9)
has subsequently enabled the creation of RNA-guided
DNA binding domains, where the specificity of genome tar-
geting can be altered by changing the 20 nt spacer sequence
within a single guide RNA (sgRNA) composed of a fused
crRNA and tracrRNA (5). A number of groups have subse-
quently generated synthetic transcription factors by fusing
transactivation domains to dCas9 (6,7). Cas9 derived syn-
thetic transcription factors have been employed for a num-
ber of applications including; genetic circuits (8), cell repro-
gramming (9) and biosensors (10).
It is important to note that Cas9 represents only one of a
variety of known CRISPR systems, with others possessing
divergent and useful properties. In particular Cas12a (for-
merly Cpf1), similarly to Cas9, functions as an RNA-guided
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homing endonuclease. However, unlike Cas9, Cas12a can
be targeted by a single crRNA (∼40 nucleotides (nt)) as
opposed to requiring a combined crRNA and tracrRNA
(∼100 nt) (11). Furthermore, in contrast to Cas9, Cas12a
possesses RNase activity and can recognise and process an
array of adjacent crRNAs within a single transcript to en-
able targeting of the protein to multiple unique loci (12).
Whilst work has been carried out to generate synthetic
transcription factors using DNase dead dCas12a variants
from Acidaminococcus sp. BV3L6 and Lachnospiraceae bac-
terium ND206 (AsCas12a and LbCas12a respectively) (13),
the related Francisella novicida variant (FnCas12a) has
remained understudied, as initial work suggested it may
not cut DNA in vivo (11). However, subsequent work by
Kim et al. showed it did possess activity in mammalian
cells (14). FnCas12a was initially characterised as hav-
ing a shorter PAM sequence than AsCas12a or LbCas12a
in vitro, ‘TTN’ for the Fn variant compared to ‘TTTN’
for the As and Lb variants. (11). Subsequent cleavage
assays in mammalian cells has shown a PAM sequence
‘K(G/T)Y(C/T)TV(A/C/G)’ enables optimal targeting for
FnCas12a (15), compared to ‘TTTV’ for both AsCas12a
and LbCas12a (16). ‘KYTV’ can on average be found ev-
ery 21 nt. This targeting density is highly comparable to the
targeting capacity of SpCas9 which has a PAM sequence
‘NGG’, which can on average be found every 16 nt. In con-
trast, the As/LbCas12a PAM sequence ‘TTTV’ can only be
found on average every 85 nt.
The ability to target more synthetic transcription fac-
tors to a specific genomic region becomes essential in cases
where narrow windows of targeting are optimal and in par-
ticular, when carrying out multiplexed targeting. One clear
example is the case of gene network manipulation, where;
(i) there is a 350 nt window within the promoter region
where optimal transactivation is observed (17), (ii) multiple
promoters will be simultaneously targeted and (iii) multiple
studies including this work show that targeting more than
one copy of the synthetic transcription factor to the same
promoter can enable enhanced transactivation (13,18).
In the following work, we show that FnCas12a can
be engineered and applied as a synthetic transcription
factor in mammalian cells, by fusing the VPR domain
composed of a tri-partite activator containing VP64, P65
and Rta to the C-terminus (19). We subsequently ex-
plore whether dFnCas12a-VPR shows orthogonality when
screened alongside dAsCas12a-VPR and dLbCas12a-VPR.
We then test whether single crRNAs are sufficient for gene
activation and look for synergistic transactivation when
multiple crRNA target a single promoter. We further ex-
plore multiplexed activation from single crRNA arrays
as well as assessing the role of position of targeting cr-
RNA within 6-crRNA arrays on the capacity to trans-
activate targeted genes. Finally, we explore the genera-
tion of split intein versions of dFnCas12a-VPR, which
provides a strategy for reducing the size of coding se-
quences that need to be packaged within delivery vectors
such as the therapeutically relevant but highly size con-
strained AAV vector. We test four split intein versions and




Isothermal mutagenesis was used to introduce amino acid
substitutions; D908A for AsCas12a, D917A for FnCas12a
and D832A for LbCas12a. Mutation of this highly con-
served amino acid has previously been shown to abolish
DNase activity (11). The VPR transactivation domain was
subcloned onto the 3′ of each dCas12a from dCas9-VPR,
restriction ligation.
Single crRNA plasmids and crRNA arrays were gener-
ated by first annealing oligos ordered from IDT (Integrated
DNA Technologies). The annealed oligos were then ligat-
ing into the BpiI (Thermo Scientific cat #ER1012) digested
pU6 plasmid backbone using 1 l of T4 PNK (NEB cat
#M0201L) and 1 l of T4 ligase (NEB cat #M0202L) in a
20 l reaction, incubated at 37◦C for 30 min before trans-
forming into Escherichia coli. Sequences for targeting gR-
NAs and crRNAs are included in Supplementary Table S1.
Designing split intein constructs
Four split intein locations were chosen based upon the pub-
lished FnCas12a protein structure (PDB: 5NFV) (20), with
locations chosen to be close to the median amino acid and
lying within exposed flexible loops within the protein struc-
ture. The split inteins NpuN and SspC cloned onto the C-
terminus and N-terminus of the first and second halves re-
spectively using Gibson assembly. The coding sequences for
each of the split constructs are provided in Supplementary
Table S3.
Cell culturing and transfection
HEK293 cells were cultured in DMEM (Gibco; Life Tech-
nologies) with 10% FBS (Gibco; Life Technologies), 4mM
glutamine and 1% penicillin-streptomycin (Gibco; Life
Technologies). Transfections were carried out a day after
seeding ∼200 000 cells per well into 24-well plates. Trans-
fections were performed using either lipofectamine 2000
(luciferase assays) or GenJet In vitro transfection reagent
(qRT-PCRs). For the initial luciferase assays 200 ng of the
synthetic transcription factor was transfected with 100 ng
of the gRNA/crRNA plasmids. For the qRT-PCR assays
500 ng of the synthetic transcription factor was transfected
with 250 ng of the gRNA/crRNA plasmids.
Dual luciferase assay
HEK293 cells were transfected with a Firefly luciferase re-
porter construct, Renilla luciferase normalising construct
and the respective synthetic transcription factor construct,
with or without a targeting crRNA/gRNA plasmid. Fire-
fly luciferase expression and Renilla luciferase expression
were then assessed using the dual-luciferase kit (Promega
E1910) with measurements carried out with the Modu-
lus II microplate reader (Turner Biosystems). In all cases
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RNA extraction and cDNA generation
72 hours after transfection cells were harvested and RNA
extraction was performed using E.Z.N.A Total RNA Kit
1 (Omega Biotek cat #R6834-01). cDNA generation was
performed using SuperScript IV Reverse Transcriptase (In-
vitrogen). 1 g of RNA was mixed with 1 l of 50M
oligo d(T)20 (IDT), 1 l of 10mM dNTP mix (Promega cat
#U1240) and DEPC water up to a final volume of 13 l in a
PCR tube and incubated at 65◦C for 5 min then on ice for 1
min. The following components were added to each sample:
4 l of SuperScript IV Reverse Transcriptase buffer, 1 l of
0.1 M DTT, 1 ul of dH20, 0.5 l of RiboLock RNase In-
hibitor (Invitrogen) and 0.5 l of SuperScript IV Reverse
Transcriptase (Invitrogen). The reactions were then incu-
bated at 52◦C for 10 min followed by 80◦C for 10 min and
holding at 4◦C.
Unless otherwise stated, cells were harvested three days
post transfection using E.Z.N.A. Total RNA Kit 1 (Omega
Biotek cat #R6834-01) according to the manufacturer’s in-
structions. The concentration and RNA quality was as-
sessed using the nanodrop.
1 l of 50 M oligo d(T)20 (IDT) and 1 l of 10 mM
dNTP mix (Promega cat #U1240) were combined with 1
g of RNA before adding dd H2O up to a final volume of
13 l. cDNA was then generated using SuperScript IV Re-
verse Transcriptase (Thermo Fisher cat #18090050) accord-
ing to the manufacturer’s instructions using 0.5 l of Ri-
boLock RNase Inhibitor (Thermo Scientific cat #EO0381)
and 0.5 l of SuperScript IV Reverse Transcriptase per sam-
ple.
qRT-PCR
The 96-well qPCR reaction plates were set up using
the Power SYBR Green qPCR mix (Thermo Fisher cat
#4367659) according to the manufacturer’s protocol, using
a 10l total reaction volume. The 96-well qPCR plate was
run on the StepOnePlus real-time PCR machine (Thermo
Fisher cat #4376600). Cycle threshold (Ct) values were cal-
culated on the StepOnePlus PCR machine software and fur-
ther analysed using the statistical analysis software, Prism
8. Primers (against target and normalising genes) utilised in
the study are outlined in Supplementary Table S2.
384-well qPCR reaction plates for the multiplexed acti-
vation of endogenous genes (Figures 5 and 7) were set up
using the Brilliant III ultra-fast SYBR master mix (Agilent
cat #600882) according to the manufacturer’s protocol, us-
ing a 4l total reaction volume. Samples were loaded on a
384-multiwell plate (Roche cat #04729749001) and ran on
the Lightcycler 480 qPCR machine. The Ct values were ob-
tained from the Lightcycler software. Ct was calculated
by subtracting the mean Ct value for the gene of interest
from the mean Ct value for the normalising gene in each
experiment. Next the Ct was calculated by subtracting
the Ct value for each sample from the Ct value for the
respective negative control. Finally, relative gene expression
was calculated by calculating 2–Ct for each sample. Subse-
quent statistical analysis was performed using the statistical
analysis software, Prism 8.
RESULTS
dFnCas12a-VPR transactivates Luciferase plasmid reporter
in mammalian cells
To assess the capability of different Cas12a systems to be
adapted as synthetic transcription factors, three variants of
Cas12a were chosen. The As, Lb and Fn variants were se-
lected due to their well characterised nature (As and Lb) or
the wide targeting range of the PAM sequence (Fn). DNase
inactive variants were generated before the VPR transacti-
vation domain was cloned onto the 3′end of each dCas12a.
The three variants (As, Fn and Lb) were initially screened
alongside dCas9-VPR using a dual luciferase assay. Uti-
lizing a dual plasmid reporter system (21), each of the
dCas12a-VPR constructs and dCas9-VPR were targeted
upstream of a Firefly luciferase gene using the respective
crRNAs (dCas12a-VPR variants) or sgRNA (dCas9-VPR)
(Figure 1A).
The plasmids expressing the synthetic transcription fac-
tor and crRNA/sgRNA were co-transfected alongside the
targeted Firefly luciferase plasmid and a control Renilla lu-
ciferase plasmid (Figure 1B) into HEK293 cells. Two days
post-transfection the ratio of the targeted Firefly luciferase
to the normalising Renilla luciferase was measured for each
variant with or without a targeting gRNA/crRNA (Sup-
plementary Figure S1) and the ratio for the respective tar-
geted and non-targeted conditions could then be calcu-
lated (Figure 1C). Of interest the targeted Fn variant of
dCas12a-VPR showed significant transactivation over the
non-targeted control (62-fold, P = 0.027 based on two-
tailed students t-test) and displayed non-significantly higher
transactivation when compared to the As and Lb variants
using a Tukey’s multiple comparisons test.
Orthogonality observed between dCas12a-VPR variants
We subsequently sought to test for orthogonality between
the three dCas12a-VPR variants (Figure 2A). The activity
of each dCas12a-VPR variant when delivered with crRNAs
from each of the variants was normalised to transfection
without a targeting crRNA, measured using the dual lu-
ciferase assay previously described (Figure 1B).
When a Dunnett’s multiple comparisons test was per-
formed to test the fold transactivation of the dCas12a-VPR
constructs delivered with each targeting crRNA compared
to without a crRNA, we see that only the cognate crRNAs
show significant transactivation for each of the three vari-
ants. Of note dAsCas12a-VPR delivered with the Fn cr-
RNA shows potential albeit non-significant cross reactiv-
ity (P = 0.17). In contrast dFnCas12a-VPR delivered with
the Lb crRNA and dLbCas12a-VPR delivered with the Fn
crRNA show particularly low significance (P = 0.993 and
P = 0.999 respectively), suggesting they could serve as an
orthogonal pair (Figure 2B).
Single crRNAs are sufficient for transactivation of endoge-
nous genes
Having demonstrated the activity of dFnCas12a-VPR us-
ing a plasmid-based reporter, we next sought to test whether
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Figure 1. Screening dCas12a-VPR constructs using plasmid-based Firefly luciferase reporter. (A) Schematic representation of the targeted promoter region
within the Firefly Luciferase reporter plasmid. The top strand of the promoter region contains six repeated binding sequences for the dCas12a constructs
(dark blue) with adjacent PAM sequences that can be recognised by all three variants ‘TTTC’ (orange). The bottom strand of the promoter region contains
six repeated binding sequences for dCas9-VPR (light blue) with adjacent PAM sequences that can be recognised by dCas9-VPR (purple). (B) Diagrammatic
representation of the dual luciferase reporter assay. A non-targeted Renilla luciferase plasmid was co-transfected with the targeted Firefly luciferase reporter
plasmid, to enable normalisation of the relative Firefly luciferase activity between test and control conditions. If a putative synthetic transcription factor
was able to transactivate the targeted Firefly luciferase gene, then the ratio of Firefly to Renilla luciferase activity would be increased compared to the
negative control condition. (C) Testing the three dCas12a-VPR variants alongside dCas9-VPR using the dual luciferase assay. Each construct is delivered
with a targeting crRNA/gRNA and the resulting ratio is normalised to the ratio when delivered without a crRNA/gRNA. The results represent three
biological replicates and the error bars display the SEM.
three genes HBB, ASCL1 and IL1RN were chosen for tar-
geting as they had been found to be especially amenable
to transactivation when targeted with dCas9 based syn-
thetic transcription factors (22). Six crRNAs were designed
to target each of the three respective promoters. The cr-
RNAs were designed to utilise a ‘TTV’ PAM sequence
within a window 50–300 nt upstream of the transcrip-
tion start site (TSS) (Figure 3A). These TSS were identi-
fied using Fantom5 software (23), available within UCSC
genome browser, which maps TSSs using capped analy-
sis of gene expression (CAGE) data. This window was se-
lected as previous work had shown maximal transactiva-
tion of endogenous genes was obtained when targeting
this window with a Cas9 derived synthetic transcription
factor (17).
The crRNA plasmids were individually transfected
alongside dFnCas12a-VPR into HEK293 cells. Three days
post transfection, the total RNA were extracted for qRT-
PCR. When assessing the gene expression across all three
genes using a Dunnett’s multiple comparisons test we found
three functional crRNA for HBB that showed significant
activation (H1, H2 and H4; with P = 0.0028, P = 0.0011
and P = 0.0253 respectively), and one crRNA each for
ASCL1 (A2, with P = 0.0003) and IL1RN (I2, with
P = 0.0002) (Figure 3B). These results showed that a single
crRNA was sufficient to enable transactivation of endoge-
nous genes.
Targeting multiple crRNAs enhances transactivation with ev-
idence for synergy
Having shown that targeting dFnCas12a-VPR using single
crRNAs was sufficient for transactivation, we next explored
if the targeting of multiple crRNAs to the same promoter
further enhanced gene expression synergistically. For each
gene, the two individual crRNAs that showed the highest
fold up-regulation were screened for transactivation, com-
paring their activity when co-transfected compared to in-
dividually transfected. For HBB and IL1RN a further cr-
RNA pair was selected from crRNAs which had shown ei-
ther weak or no significant transactivation (H4 + H5 and
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Figure 2. Testing for orthogonality between different dCas12a-VPR variants. (A) Schematic representation of the testing of orthogonality using either native
(e.g. dAsCas12a-VPR with As crRNA) or non-native (e.g. dAsCas12a-VPR with Fn crRNA) crRNA pairings. (B) The three dCas12a-VPR variants (As, Fn
and Lb) were screened for orthogonality using the dual luciferase assay (as described in Figure 1B). Each dCas12a-VPR construct was delivered with each
of the three targeting crRNA (As, Fn or Lb) or no targeting crRNA. Results display the mean luciferase activity when each of the three targeting crRNAs
are transfected, normalised to the mean luciferase for the respective no targeting crRNA condition. Results correspond to three biological replicates, error
bars show SEM and the stars (*) denote significant (P < 0.05) expression relative to no crRNA based on a Dunnett’s multiple comparisons test.
delivering two crRNAs compared to individual crRNAs,
equimolar concentrations of crRNA plasmids were deliv-
ered to HEK293 cells.
Analysis by qRT-PCR showed the mean increase in
mRNA abundance for the co-transfected condition was
consistently higher than the most active individual crRNA
(Figure 4A), with one notable exception (IL1RN crRNA
2 + 5) discussed below. When a two tailed t-test was per-
formed between the co-transfected and most active indi-
vidual crRNA conditions, we saw a significant increase in
mRNA abundance for; HBB crRNA 1 + 2 (P = 0.017),
ASCL1 crRNA 2 + 4 (P = 0.001), and IL1RN crRNA 4 + 6
(P = 0.005). We also observed a non-significant increase in
mRNA abundance for HBB crRNA 4 + 5 (P = 0.0875).
For one of the tested crRNA pairs (IL1RN crRNA 2 and 5)
the spacer sequences had partial complementarity (12 nu-
cleotides). This may explain the small decrease in mRNA
abundance observed when comparing co-transfection to
IL1RN crRNA 2 individually (non-significant, P = 0.117).
As a result, the IL1RN crRNA 2 + 5 pair was excluded from
subsequent analysis.
As one of the advantages of Cas12a is the capacity to pro-
cess crRNA arrays, we sought to test whether 2-crRNA ar-
rays, consisting of a pair of crRNAs in tandem, could be
utilised by dFnCas12a-VPR for transactivating target genes
and whether these short arrays would enable increased or
synergistic activation compared to the delivery of individ-
ual crRNAs. To test this, 2-crRNA arrays were constructed
using the most active crRNA pairs from the preceding ex-
periments. Three days after transfection into HEK293 cells,
the fold upregulation induced using these arrays was tested
and compared to the co-transfected crRNAs and a non-
targeting crRNA control. We consistently observed that the
crRNA arrays performed as well if not better than the co-
transfected crRNAs, with a higher mean fold upregulation
for the arrays compared with the co-transfected crRNAs in
all cases (Figure 4B).
We subsequently sought to test the crRNA arrays for evi-
dence of synergistic transactivation. Synergy is here defined
as showing greater transactivation than would be expected
from adding the transactivation caused by each individual
crRNA. To test this a hypothetical additive distribution was
calculated by summing the distributions for the single cr-
RNA conditions (Supplementary Note 1). Two tailed t-tests
were then used to check whether significantly greater acti-
vation was seen for the array conditions than their respec-
tive hypothetical additive distributions. We saw that syn-
ergy was indeed observed for two of the cases, HBB (1 + 2)
array (P = 0.0027) and HBB (4 + 5) array (P = 0.0027)
(Supplementary Figure S2). Significance was not achieved
for the ASCL1 array (P = 0.1891) or the IL1RN array
(P = 0.1069). These results showed that pairs of targeting
crRNA expressed from a single array can induce significant
up-regulation, which in some cases was significantly higher
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Figure 3. Testing single crRNAs for endogenous gene activation. (A) dFnCas12a-VPR was screened for activity targeting three endogenous genes; HBB,
ASCL1 and IL1RN in HEK293 cells using single crRNAs. The promoter of each gene was targeted with six single crRNAs and transcriptional upregulation
was compared to a non-targeting (NT) crRNA. (B) The change in transcript abundance was then measured using qRT-PCR, with results shown for the
three biological replicates, with the error bars showing SEM. Stars (*) show results with a P value < 0.05 after one-way ANOVA followed by a post-hoc
Dunnetts test to compare the expression of each targeting crRNA relative to the non-targeting negative control.
Multiplexed activation from crRNA arrays
Having observed that transactivation of individual genes
could be achieved using arrays with dFnCas12a-VPR, we
next sought to test longer arrays designed to target multiple
genes simultaneously, while exploring the impact of crRNA
order within the array on activity. To achieve this, the most
active crRNA arrays from the previous experiment (Figure
4B) were utilised for the generation of 6-crRNA arrays. Six
different arrays were designed with three pairs of crRNAs,
such that each pair targeted one of three promoters (Fig-
ure 5A). Using this design, all six combinations could be
explored to not only test for significant multiplexed activa-
tion but also test whether changing the position or flank-
ing crRNA sequences impacted the capacity of a crRNA
array to induce transactivation. The constructs were trans-
fected, with the respective targeting 2-crRNA array (grey
bars) serving as a positive control. A Dunnett’s multiple
comparisons test was performed to test whether each 6-
crRNA array showed significant transactivation above the
negative control. The results showed that each crRNA ar-
ray was able to induce multiplexed activation, with sig-
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Figure 4. Enhanced activation observed with co-expression of targeting crRNAs. (A) The most active individual crRNAs (from Figure 3) were delivered
individually or co-transfected into HEK293 cells. The RNA abundance for each targeted gene was then measured by qRT-PCR and normalised to RNA
expression when dFnCas12a-VPR was delivered with a non-targeting (NT) crRNA. The pair IL1RN crRNA 2 and IL1RN crRNA 5 were excluded as
the spacer sequences overlapped. Results from three biological replicates were measured by qRT-PCR and normalised to delivery with a non-targeting
crRNA, with stars (*) showing results with a P value <0.05 based on Tukey’s multiple comparison test and error bars showing SEM. (B) The crRNA pairs
were incorporated into a single 2-crRNA array and the activity of this array was screened compared to the co-transfection of the single crRNAs. Results
from three biological replicates were measured by qRT-PCR and normalised to delivery with a non-targeting crRNA, with stars (*) showing results with
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Figure 5. Multiplexed activation of endogenous genes. (A) The left panel shows a schematic of the most active crRNA array for targeting each of the three
genes from Figure 4B. The right panel shows the designs of the combinatorial 6-crRNA arrays for screening for multiplexed activation. The six arrays
were designed to ensure each of the pairs of crRNAs would be present in the first and second, third and fourth or fifth and sixth positions within the
6-crRNA arrays. (B) The six arrays were separately transfected into HEK293 cells alongside dFnCas12a-VPR and the expression for each of the three
targeted genes was assessed by qRT-PCR, normalising to the expression with a non-targeting crRNA. The grey bars showing the relative expression for the
respective targeting 2-crRNA array, serving as a positive control. The results from the three biological replicates are displayed based upon the position of
the respective targeting crRNAs within the 6-crRNA arrays, with stars (*) showing results with a P value <0.05 based on Dunnett’s multiple comparisons
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Figure 6. Position dependent activity within pol3 derived crRNA arrays. (A) Design of arrays constructed for testing the impact of position for a single
targeting crRNA within a 6-crRNA array. (B) qRT-PCR analysis of ASCL1 mRNA abundance for the six arrays after transfection into HEK293 cells,
with the graph showing results from the three biological replicates, error bars displaying SEM and stars (*) showing results with a P value <0.05 based on
a Dunnett’s multiple comparison test.
Figure 7. Testing split intein dFnCas12a-VPR for multiplexed transactivation. The two most active split versions from initial testing were screened for
activity by transiently transfecting each half or both halves alongside the targeting crRNA array IAH. The graphs display qRT-PCR results from three
biological replicates looking at transactivation of the respective genes normalised to the full length dFnCas12a-VPR delivered without a targeting crRNA.
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Modest order dependent array activity observed for individual
and paired crRNA
For all three genes targeted, there appeared to be a clear
correlation between the position of the targeting crRNAs
within the arrays and the fold up-regulation. More specif-
ically when the gene targeting crRNAs were positioned
closer to the 3′ end of the array, increases in mRNA abun-
dance were consistently diminished across all three genes
tested (Figure 5B). When simple linear regression was per-
formed, a strong inverse correlation between the targeting
crRNA position within an array and gene activation of
the targeted gene was observed for IL1RN (R2 = 0.8457,
P < 0.0001), whilst weaker inverse correlations were ob-
served for ASCL1 and HBB (R2 = 0.4160, P = 0.0039 and
R2 = 0.4876, P = 0.0013, respectively) (Supplementary Fig-
ure S3).
To inspect the relationship of crRNA location and acti-
vation strength at a higher resolution, a series of crRNA
arrays were generated where each array possessed a single
targeting crRNA and five non-targeting crRNAs. The non-
targeting crRNAs were rationally designed from different
randomly generated 20 nucleotide sequences, that showed
no perfect matches against the human genome.
Six different versions of the array were generated so that
all positions of the targeting crRNA (ASCL1 crRNA 2)
within the array could be tested (Figure 6A). An initial
Dunnett’s multiple comparisons test was performed to test
whether each of the 6-crRNA arrays showed significant
transactivation of ASCL1 above the negative control. The
results showed significant transactivation for all six arrays,
however we also observed a reduction in transactivation of
ASCL1 as the targeting crRNA was positioned closer to
the 3′ of the array, with the highest mean fold-upregulation
(103-fold) when the crRNA was at the first (most 5′) posi-
tion and the lowest fold up-regulation (29-fold) when the cr-
RNA was at the last position (most 3′) (Figure 6B). When
simple linear regression was performed, a weak reduction
in activity when the targeting crRNAs were positioned to-
wards the 3′ of the arrays was observed (R2 = 0.3671,
P = 0.0077) (Supplementary Figure S4). While a broader
trend of reduction in activity is still observed when a single
targeting crRNA is expressed at different positions within
an array, we see that there are local deviations at some posi-
tions (such as Pos4). This may be due to other factors which
contribute to crRNA array stability and processing through
changes in RNA sequence and structure.
Split intein dFnCas12a-VPR retains activity for multiplexed
transactivation
Having established dFnCas12a-VPR as a potent activa-
tor and characterised it in detail, we next sought to en-
hance its value in biotechnological applications. In its cur-
rent form the dFnCas12a-VPR coding sequence is too long
to be packaged into Adeno-associated viruses, a low im-
munogenicity delivery vector, for clinical focussed applica-
tions (24). To address this, we sought to utilise a chimeric
split intein system using the N-terminal fragment of Npu
and the C-terminal fragment of SspC (NpuN-SspC) (25).
The NpuN-SspC split intein system should enable the
dFnCas12a-VPR protein to be expressed as halves from two
different constructs before trans-splicing to form a contigu-
ous protein in vivo (Supplementary Figure S5A).
To test this strategy, we generated four rationally de-
signed split versions (further described in methods) (Sup-
plementary Figure S5B), with initial tests suggesting that
two of these permitted transactivation (version 1 and ver-
sion 2 – Supplementary Figure S6). We sought to further
test these two versions and see whether they could be used
for multiplexed up-regulation from a single crRNA array.
To test this, both halves were delivered alongside the IAH
array used in the previous experiment (Figure 5B). This
was chosen as it enabled comparable fold-changes in acti-
vation for all three of the genes targeted. A Dunnett’s mul-
tiple comparisons test was performed to test whether any of
the individual halves or co-delivered halves showed signifi-
cant transactivation above the negative control (full length
dFnCas12a-VPR without a targeting crRNA). The results
showed that significant transactivation of all three genes
could be achieved with version 2, with version 1 only induc-
ing significant transactivation for two of the targeted genes
(Figure 7). As such we show the successful reconstitution
of split intein dFnCas12a-VPR for multiplexed transacti-
vation of human genes.
DISCUSSION
Here, we have shown the first application of engineering
FnCas12a derived synthetic transcription factors in mam-
malian cells. The key advantage of the Fn variant is the sim-
pler PAM sequence ‘KYTV’ when compared to the com-
monly utilised As or Lb variants ‘TTTV’.
This translates to being able to target on average every 21
nt as opposed to on average every 85 nt, highly compara-
ble to the Cas9 PAM sequence ‘NGG’ which enables tar-
geting on average every 16 nt. This allows much denser tar-
geting, with more potential targets within any given length
of DNA. This is of particular interest for transactivation
of target genes as we have also highlighted that delivery
of multiple active crRNAs targeting the same promoter re-
gion further enhances up-regulation, showing evidence of
synergistic transactivation for some targets. When screen-
ing the three variants for orthogonality, we see evidence
for orthogonality in particular for the pairing, dFnCas12a-
VPR and dLbCas12a-VPR with no significant transactiva-
tion observed when they are co-transfected with the recip-
rocal crRNA. Such orthogonality is very important when
considering applications where two different functionalities
are being encoded on two separate proteins. In these cases it
is critical that the crRNAs for targeting one of the proteins
does not lead to inadvertent targeting of the other protein.
For example when looking to induce transactivation of a set
of target genes and repression of a different set, cross-talk
between the two dCas12a-VPR/crRNA pairs would con-
found the intended activity.
We found that dFnCas12a-VPR can be used for multi-
plexed transactivation of three different genes from a single
transcript. Due to the relative ease of construction of these
crRNA arrays, compared to assembling multiple gRNAs
for Cas9 based systems, this simplifies the targeting of mul-
tiple genes for simultaneous transactivation. We have con-
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sitioned closer to the 3′ of crRNA arrays expressed from
the U6 pol 3 promoter. This information can inform design
constraints when targeting multiple genes for upregulation
from a single array. In particular, arrays can be designed
to express crRNAs closer to the 5′ end of an array where
they target genes that are challenging to upregulate or where
higher overexpression is desired. Conversely, crRNAs tar-
geting genes that are easier to up-regulate or where lower
over-expression is desired can be positioned closer to the 3′
end of an array.
One likely explanation for the reduction of activity as the
crRNA is positioned closer to the 3′ end of the array is that
crRNA abundance is reduced. Zetsche et al. showed with
RNA-seq data a decreased crRNA abundance towards the
3′ of a 3-crRNA array when expressed in HEK293 cells (26).
This may be due to the presence of a weak non-canonical
Pol III terminator sequence ‘TTTCT’ (27) within all of the
direct repeats within the crRNA array.
Whilst previous work has explored the role of PAM se-
lection (28) and spacer sequence choice (29) on crRNA ac-
tivity, to our knowledge this is the first time where order-
dependent activity of hU6 expressed crRNA arrays have
been shown. This is of key relevance to researchers as U6
promoters naturally highly express short non-coding RNA,
with a defined termination sequence of five thymidines. As
such the majority of gRNA/crRNA mammalian expression
plasmids utilise this promoter and the findings of order de-
pendent activity will have relevance to researchers working
with Cas12a or derived synthetic transcription factors. In
particular the order dependent activity of crRNAs within
an array also points to an alternate approach for diversi-
fying the fold change of transactivation of different genes
within genetic networks and pathways. This may open up
opportunities for streamlined manipulation of pathways.
For example, the promoters of multiple genes within a path-
way can be targeted by the same crRNA but in different or-
derings. Subsequent sequencing of high production strains
can reveal the enrichment of order for specific crRNAs,
which in turn reveals when higher transactivation or re-
duced transactivation of a specific gene within a pathway
are being selected for. This in turn can help to reveal key
bottlenecks or toxicities that emerge. A similar approach
can be considered for processes such as cell reprogramming
and indeed any process where transcriptional modulation
of a gene network can be correlated with a phenotype.
Finally, we identified a split version of dFnCas12a-VPR,
allowing the coding sequence to be expressed separately and
reconstituted through post-translational splicing when co-
delivered. This not only increases potential avenues for co-
ordinating activity due to the dependence of both halves be-
ing expressed, but further by splitting the coding sequence,
the sizes of the genetic constructs fall within the packaging
constraints of AAV vectors opening future avenues for ther-
apeutic delivery.
Through this expansion of the Cas12a toolkit researchers
can simultaneously transactivate multiple genes with ease,
with the capacity to densely target multiple promoters. In
addition, the compact nature of the crRNA array both facil-
itates cheap and easy construction using short oligo-based
assembly strategies. Furthermore the compact arrays ex-
pand the potential of CRISPR systems when considering
AAV viral delivery for therapeutic applications especially
when paired with our split Cas12a strategy or alternate ap-
proaches (30).
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